Ask us a question 520 547-3440 info@c-path.org

Subscribe

Home
About
Programs
Sharing Knowledge that Leads to Innovation
ACTIVE CONSORTIA / PROGRAMS

BmDR

Biomarker Data Repository

MSOAC

Multiple Sclerosis Outcome Assessments Consortium

CPA-1

Critical Path for Alpha-1 Antitrypsin Deficiency

PRO Consortium

Patient-Reported Outcome Consortium

CPAD

Critical Path For Alzheimer’s Disease

PKDOC

Polycystic Kidney Disease Outcomes Consortium

CPP

Critical Path for Parkinson’s

PredicTox KE

PredicTox Knowledge Environment

CP-RND

Critical Path for Rare Neurodegenerative Diseases

PSTC

Predictive Safety Testing Consortium

CP-SCD

Critical Path for Sickle Cell Disease

QuantMed

Quantitative Medicine Program

CPTA

Critical Path to Therapeutics for the Ataxias

RDCA-DAP

Rare Disease Cures Accelerator-Data and Analytics Platform

CDRC

CURE Drug Repurposing Collaboratory

RD-COA Consortium

Rare Disease Clinical Outcome Assessment Consortium

DCC

Data Collaboration Center

TB-PACTS

TB-Platform for Aggregation of Clinical TB Studies

D-RSC

Duchenne Regulatory Science Consortium

TTC

Transplant Therapeutics Consortium

eCOA Consortium

Electronic Clinical Outcome Assessment Consortium

TOMI-T1D

Trial Outcome Markers Initiative in T1D Consortium

FA-ICD

Friedreich’s Ataxia Integrated Clinical Database

TRxA

Translational Therapeutics Accelerator

HD-RSC

Huntington’s Disease Regulatory Science Consortium

T1D

Type 1 Diabetes Consortium

INC

International Neonatal Consortium

Completed Consortia

CFAST

Coalition for Accelerating Standards & Therapies

PTC

Pediatric Trials Consortium

CPTR

Critical Path to TB Drug Regimens
C-Path in Europe
Tools & Platforms
Training
Impact
News & Events
- Events
- News
- Videos
- Publications
- Presentations
- Press Releases
Make a Gift

News

Home>News & Events>Presentations>PSTC>The Role of Safety Biomarkers in Predictive Toxicology

58

Presentations

October 16, 2014 PRINT PDF

The Role of Safety Biomarkers in Predictive Toxicology

Related Posts

Advancing Adoption of Novel Safety Biomarkers into Drug Development through Voluntary Submission of Data at US FDA, EMA, and PMDA
Evaluation of Novel Biomarkers of Nephrotoxicity in Monkeys Treated with Gentamicin
Kidney Injury Biomarkers Lipocalin-2, Clusterin and Albumin, but Not Kidney Injury Molecule 1, Are More Sensitive Than Traditional Markers of Gentamicin-Induced Kidney Injury in Beagles
Evaluation of an In Vitro Model of Spermatogenesis for Predicting Testicular Toxicity
Rapid Immunoassay Development and Evaluation of ICAM-1 and E-Selectin As Potential Biomarkers of Vascular Injury in Rats

FAQ
Annual Reports
Employment
Contact
Terms of Use
Policies
GDPR SCCs
Privacy Policy
Explore C-Path
Donate

C-Path Main Office 1730 E. River Rd., #200
Tucson, AZ. 85718
Tel: 520-547-3440
Fax: 520-547-3456 C-Path Global Ltd. 33 Sir John Rogerson’s
Dublin 2, Ireland

Ask us a question Tel: 520-547¬3440
Email: info@c-path.org Subscribe

x

Thank you for your interest in the MIDD Training Course.

Please click to follow the appropriate link below to complete your application

Contact Us

Name

Email

Phone

Message

Contact Us

Name

Email

Phone

Message